Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
PTIE's Cash to Debt is ranked higher than
83% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. PTIE: No Debt )
PTIE' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
PTIE's Interest Coverage is ranked higher than
63% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PTIE: No Debt )
PTIE' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 81.29
M-Score: 6.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 76.28
PTIE's Operating margin (%) is ranked higher than
99% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. PTIE: 76.28 )
PTIE' s 10-Year Operating margin (%) Range
Min: -644.04   Max: 76.28
Current: 76.28

-644.04
76.28
Net-margin (%) 76.71
PTIE's Net-margin (%) is ranked higher than
98% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. PTIE: 76.71 )
PTIE' s 10-Year Net-margin (%) Range
Min: -603.74   Max: 76.71
Current: 76.71

-603.74
76.71
ROE (%) 65.31
PTIE's ROE (%) is ranked higher than
99% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. PTIE: 65.31 )
PTIE' s 10-Year ROE (%) Range
Min: -49.23   Max: 65.31
Current: 65.31

-49.23
65.31
ROA (%) 62.96
PTIE's ROA (%) is ranked higher than
100% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. PTIE: 62.96 )
PTIE' s 10-Year ROA (%) Range
Min: -47.66   Max: 62.96
Current: 62.96

-47.66
62.96
Revenue Growth (%) 32.60
PTIE's Revenue Growth (%) is ranked higher than
93% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. PTIE: 32.60 )
PTIE' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 129.5
Current: 32.6

0
129.5
» PTIE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

PTIE Guru Trades in Q2 2013

Jean-Marie Eveillard 1,862,099 sh (+171.01%)
Jim Simons 981,972 sh (+8.4%)
Murray Stahl 38,000 sh (unchged)
Mario Gabelli 295,000 sh (-15.71%)
» More
Q3 2013

PTIE Guru Trades in Q3 2013

Jean-Marie Eveillard 2,431,935 sh (+30.6%)
Murray Stahl 38,000 sh (unchged)
Jim Simons 974,683 sh (-0.74%)
Mario Gabelli 250,000 sh (-15.25%)
» More
Q4 2013

PTIE Guru Trades in Q4 2013

Steven Cohen 11,497 sh (New)
Jean-Marie Eveillard 2,927,386 sh (+20.37%)
Murray Stahl Sold Out
Mario Gabelli 190,000 sh (-24%)
Jim Simons 555,583 sh (-43%)
» More
Q1 2014

PTIE Guru Trades in Q1 2014

George Soros 103,700 sh (New)
Jean-Marie Eveillard 3,663,750 sh (+25.15%)
Steven Cohen Sold Out
Mario Gabelli 180,000 sh (-5.26%)
Jim Simons 401,487 sh (-27.74%)
» More
» Details

Insider Trades

Latest Guru Trades with PTIE

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-03-31 New Buy0.01%$3.92 - $5.71 $ 4.8-5%103700
Jean-Marie Eveillard 2014-03-31 Add 25.15%0.01%$3.92 - $5.71 $ 4.8-5%3663750
Jean-Marie Eveillard 2013-12-31 Add 20.37%0.01%$2.61 - $4.73 $ 4.827%2927386
Mario Gabelli 2013-12-31 Reduce -24%$2.61 - $4.73 $ 4.827%190000
Jean-Marie Eveillard 2013-09-30 Add 30.6%$2.21 - $3.11 $ 4.892%2431935
Jean-Marie Eveillard 2013-06-30 Add 171.01%0.01%$2.21 - $5.41 $ 4.859%1862099
Jean-Marie Eveillard 2013-03-31 Add 30.53%$2.47 - $3.74 $ 4.860%687099
Jean-Marie Eveillard 2012-12-31 Add 163.2%$2.42 - $5.83 $ 4.831%526408
Jean-Marie Eveillard 2012-09-30 New Buy$3.57 - $5.29 $ 4.814%200000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 7.90
PTIE's P/E(ttm) is ranked higher than
98% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PTIE: 7.90 )
PTIE' s 10-Year P/E(ttm) Range
Min: 5.82   Max: 76.12
Current: 7.9

5.82
76.12
P/B 4.80
PTIE's P/B is ranked higher than
75% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. PTIE: 4.80 )
PTIE' s 10-Year P/B Range
Min: 1.55   Max: 15.03
Current: 4.8

1.55
15.03
P/S 5.50
PTIE's P/S is ranked higher than
53% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. PTIE: 5.50 )
PTIE' s 10-Year P/S Range
Min: 0   Max: 32.26
Current: 5.5

0
32.26
EV-to-EBIT 6.00
PTIE's EV-to-EBIT is ranked higher than
98% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PTIE: 6.00 )
PTIE' s 10-Year EV-to-EBIT Range
Min: 0.1   Max: 1338.1
Current: 6

0.1
1338.1
Shiller P/E 57.50
PTIE's Shiller P/E is ranked higher than
94% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PTIE: 57.50 )
PTIE' s 10-Year Shiller P/E Range
Min: 34.57   Max: 451
Current: 57.5

34.57
451
Current Ratio 29.20
PTIE's Current Ratio is ranked higher than
98% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. PTIE: 29.20 )
PTIE' s 10-Year Current Ratio Range
Min: 5.33   Max: 61.08
Current: 29.2

5.33
61.08
Quick Ratio 29.20
PTIE's Quick Ratio is ranked higher than
98% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. PTIE: 29.20 )
PTIE' s 10-Year Quick Ratio Range
Min: 5.33   Max: 61.08
Current: 29.2

5.33
61.08

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.80
PTIE's Price/Net Cash is ranked higher than
92% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 65.19 vs. PTIE: 4.80 )
PTIE' s 10-Year Price/Net Cash Range
Min: 1.08   Max: 30.22
Current: 4.8

1.08
30.22
Price/Net Current Asset Value 4.80
PTIE's Price/Net Current Asset Value is ranked higher than
91% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 44.88 vs. PTIE: 4.80 )
PTIE' s 10-Year Price/Net Current Asset Value Range
Min: 1.08   Max: 11.83
Current: 4.8

1.08
11.83
Price/Tangible Book 4.80
PTIE's Price/Tangible Book is ranked higher than
81% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. PTIE: 4.80 )
PTIE' s 10-Year Price/Tangible Book Range
Min: 1.02   Max: 11.43
Current: 4.8

1.02
11.43
Price/DCF (Projected) 240.00
PTIE's Price/DCF (Projected) is ranked higher than
89% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PTIE: 240.00 )
PTIE' s 10-Year Price/DCF (Projected) Range
Min: 0.77   Max: 275
Current: 240

0.77
275
Price/Median PS Value 0.50
PTIE's Price/Median PS Value is ranked lower than
51% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. PTIE: 0.50 )
PTIE' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 2.91
Current: 0.5

0.3
2.91
Price/Graham Number 1.30
PTIE's Price/Graham Number is ranked higher than
97% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PTIE: 1.30 )
PTIE' s 10-Year Price/Graham Number Range
Min: 1.1   Max: 3.77
Current: 1.3

1.1
3.77
Earnings Yield (Greenblatt) 16.60
PTIE's Earnings Yield (Greenblatt) is ranked higher than
83% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. PTIE: 16.60 )
PTIE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 754.5
Current: 16.6

0.1
754.5
Forward Rate of Return (Yacktman) -0.98
PTIE's Forward Rate of Return (Yacktman) is ranked higher than
86% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. PTIE: -0.98 )
PTIE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.4   Max: 23.1
Current: -0.98

-1.4
23.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PX9.Germany
Pain Therapeutics, Inc., a Delaware corporation was incorporated in May 1998. The Company is a biopharmaceutical company that develops novel drugs. The Company has four drug candidates in clinical programs, including REMOXY, PTI-202, PTI-721 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma. Its drug candidate is called REMOXY. REMOXY is a strong painkiller with a unique formulation designed to reduce potential risks of unintended use. REMOXY is a novel controlled-release oral capsule form of oxycodone in a viscous liquid formulation matrix that includes novel excipients. It is developing a novel drug candidate called PTI-188 to treat metastatic melanoma, a deadly form of skin cancer. PTI-188 is a monoclonal antibody linked to a radioisotope, intended to deliver doses of radiation lethal to melanoma tumors without harming normal tissue. It is also working on a new treatment for patients with hemophilia and also developing a pipeline of novel drug candidates in the area of oncology and hematology. The Company owns all commercial rights to its pipeline of drug candidates in oncology and hematology. It relies on a limited number of third-party manufacturers to formulate, manufacture, fill, label, ship or store all of its drug candidates. The company's strategies include Focus on Clinical Development Stage Products. It believes this focus will enable the company to generate product revenues earlier than if it was focused on early-stage research and discovery activities; Retain Significant Rights to Drugs: It currently retain worldwide commercialization rights to all of its technology and drug candidates in all markets and indications, except for REMOXY and certain other abuse-resistant drugs. The Company has an exclusive, worldwide Development and License Agreement, or the Durect Agreement, with Durect Corporation, or Durect, to use a patented technology that forms the basis for certain drug candidates, including REMOXY. Companies that currently sell generic or proprietary opioid formulations include, but are not limited to, Roxane Laboratories, Purdue Pharma, Pfizer, Abbott Laboratories, Endo Pharmaceuticals, Teva Pharmaceuticals, Elkins-Sinn, Watson Laboratories, Ortho-McNeil Pharmaceutical and Forest Pharmaceuticals. Regulation by governmental authorities in the United States and other countries is a significant factor in the manufacture and marketing of pharmaceuticals and in its ongoing research and development activities.
» More Articles for PTIE

Headlines

Articles On GuruFocus.com
Morning Coffee: Real-Time Picks May 14 2014 
Pain Therapeutics Reports Operating Results (10-K) Feb 03 2011 
Pain Therapeutics Reports Operating Results (10-Q) Oct 29 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 50,000 Shares Oct 04 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 28,597 Shares Sep 08 2010 
Pain Therapeutics (ptie) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 21,403 Shares Sep 02 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 22,391 Shares Aug 04 2010 
Pain Therapeutics Reports Operating Results (10-Q) Jul 29 2010 
Pain Therapeutics (PTIE) CEO and Chairman of the Board, 10% Owner Remi Barbier sells 27,243 Shares Jul 08 2010 
Pain Therapeutics (PTIE) CEO and Chairman of Board, 10% Owner Remi Barbier sells 50,000 Shares Jun 03 2010 

More From Other Websites
Stock Upgrades: Yo, Adrian! Netflix Doesn't Need Rocky to Pack a Punch Jul 01 2014
PAIN THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers Jun 09 2014
Pain Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference May 27 2014
PAIN THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 16 2014
PAIN THERAPEUTICS INC Financials May 16 2014
Pain Therapeutics to Present at the Bank of America Merrill Lynch 2014 Health Care Conference May 08 2014
PAIN THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report May 07 2014
PAIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition May 06 2014
Pain Therapeutics Reports Q1 2014 Financial Results May 06 2014
Q1 2014 Pain Therapeutics, Inc. Earnings Release - Time Not Supplied May 06 2014
Pain Therapeutics to Host Conference Call to Discuss Q1 2014 Financial Results Apr 30 2014
Theralase Could Light Up Cancer Therapeutics Apr 24 2014
FDA wants stronger warning labels for long-acting opioids Apr 17 2014
PAIN THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Apr 09 2014
Pain Therapeutics Invited to Present at 26th Annual ROTH Conference Mar 06 2014
Pain Therapeutics (PTIE) Enters Overbought Territory Mar 03 2014
Pain Therapeutics Invited to Present at Cowen Health Care Conference in Boston Feb 25 2014
Strength Seen in Pain Therapeutics Inc. (PTIE) Stock Surges 24% Feb 06 2014
PAIN THERAPEUTICS INC Files SEC form 10-K, Annual Report Feb 05 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide